Latest news

• Elan buys into GSK-partnered Theravance programmes for $1bn

  Aside from Breo ( known as Relvar outside the US), Elan will get royalties on sales of COPD combination therapy Anoro ( umeclidinium bromide and vilanterol), vilanterol as a monotherapy and GSK961081, a

• GSK replaces head of US operations

  GSK needs its new generation of asthma and COPD therapies - including long-acting muscarinic antagonist ( LAMA) and long-acting beta agonist ( LABA) combination Anoro ( vilanterol and umeclidinium bromide) and Advair follow-up Relvar/Breo (

• GSK trial throws everything at COPD

  All three drugs will be delivering via GSK's Ellipta inhaler, which is already used in the company's recently introduced dual therapies Anoro ( umeclidinium and vilanterol) and Relvar/Breo ( fluticasone furoate and vilanterol).

• SMC: Celgene's Abraxane 'too expensive' for Scotland

  SMC: Celgene's Abraxane 'too expensive' for Scotland. But medicines watchdog backs Sovaldi, Invokana, Defitelio, Relvar Ellipta. ... Drugs that received positive opinions included Janssen's Invokana ( canagliflozin) for type 2 diabetes, Jazz

• GSK clear to launch COPD hope Anoro in Europe

  Strengthens respiratory platform ahead of patent expiry for Advair/Seretide